RASGRP3 (RAS Guanyl Releasing Protein 3) is a member of the RASGRP family of guanine nucleotide exchange factors (GEFs) that activate RAS signaling by promoting the exchange of GDP for GTP. Primarily expressed in immune cells, including B cells, T cells, and natural killer (NK) cells, RASGRP3 plays a critical role in regulating lymphocyte development, activation, and inflammatory responses. It interacts with downstream effectors like phospholipase C gamma (PLCγ) to modulate pathways such as MAPK/ERK, influencing cell proliferation, differentiation, and apoptosis. Dysregulation of RASGRP3 has been linked to autoimmune diseases, allergies, and cancers, including melanoma and leukemia.
RASGRP3 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to detect RASGRP3 in tissue samples or cell lines. Structural studies highlight its unique domains, including a catalytic CDC25-like GEF domain, a SAM (sterile alpha motif) domain, and EF-hand motifs for calcium sensing. Research using RASGRP3 antibodies has revealed its dual role in immune regulation and oncogenesis, making it a potential therapeutic target. Commercial RASGRP3 antibodies are typically validated for specificity against recombinant proteins or knockout models to ensure reliability in experimental settings.